A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)Dan P. Zandberg, Martin J. Edelman, Kevin J. Cullen et al.|Cancer Immunology Immunotherapy|2014Cited by 75
inducTION of mage‐A3 and HPV‐16 immunity by Trojan vaccines in patients with head and neck carcinomaCaroline Voskens, Scott E. Strome, Duane A. Sewell et al.|Head & Neck|2012Cited by 67
Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10‐year experience at the University of Maryland Greenebaum Cancer CenterDan P. Zandberg, Kevin J. Cullen, Sandy Liu et al.|Head & Neck|2014Cited by 58
A phase I dose escalation trial of MAGE-A3 and HPV-16 specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).Dan P. Zandberg, Martin J. Edelman, Sandra Rollins et al.|Journal of Clinical Oncology|2014Cited by 4